May 2014 Volume 10, Issue 5
Volume 10, Issue 5 | May 2014
May 2014
In this Issue
Business & Government Policy
Mallinckrodt bets $5.6 billion on Questcor
Companies enter into deal under which they will merge to create a diversified specialty pharmaceuticals companyHorizon seeks to acquire Vidara for $660 million
Deal would be structured as a reverse merger and domicile Horizon in IrelandPatent Docs: Patent Office guidelines implementing Myriad decision cause concern
The guidelines are much broader in their determination of what is patent ineligible than was mandated by the Supreme Court’s Myriad decisionToward the first vaccine for a common infection
Respiratory syncytial virus may finally meet its match if CEVEC has its waySun rises over Ranbaxy
Sun Pharmaceutical to acquire rival Ranbaxy Laboratories for $3.2 billionDiagnostics
Four times is the charm for Theradiag
Theradiag signs a fourth microRNA partnership agreement with CNRS; company gains access to theranostics portfolio in rheumatoid arthritisBio-Rad acquires GnuBIO
Powerful in-vitro droplet technology headlines life-science acquisitionColorectal cancer test makes gains East and West
Epigenomics’ partner BioChain completes clinical validation study for Epi proColon in China; FDA panel votes favorably on testHTG and OvaGene partner on gynecologic cancer tests
Companies establish manufacturing supply agreementExpress yourself
Arno, University of Minnesota pursue gene expression in hopes of developing a companion diagnosticPreclinical
A new collaboration FORMAtion
FORMA, Celgene announce broad framework of three collaborationsUnder your skin
Microinjection device assesses drug candidates and combinations for tumorsAlbireo liver treatment on verge of human testing
A4250 shown to protect against bile acid-mediated cholestatic liver injury in miceGlioblastoma treatment produces positive results
ZIOPHARM’s DNA-based therapy slows rates of tumor growth and increases survival in miceResearch & Development
Finding a gem in GARNET
University of Virginia researchers seeking genetic markers for stroke, cardiovascular disease make breakthrough through NHGRI-supported programRevealing a mechanism of antibiotic drug resistance
Scripps Florida research findings could be used to develop a line of antibiotic drugs that are less vulnerable to bacterial mutationsBreath of fresh air
Proteostasis and Cystic Fibrosis Foundation extend collaboration to commercialize drug for most common CF mutationAlector and J&J tackle Alzheimer’s target
Alector LLC recently announced a collaborative research agreement facilitated by the California Johnson & Johnson Innovation CentersEpigenetics or bust
Roche and Oryzon partner to develop inhibitors of lysine-specific demethylase-1Discovery
Straight from the heart
Researchers identify heart disease culprit and work on therapeutic solutionG3 and Caprion partner on GLOBAL cardiovascular study
Single largest prospective pan-omic study will investigate blood- based protein biomarkers and drug targetsArgenta and Antabio announce milestone in antibacterial discovery collaboration
Argenta Discovery announced today that it has achieved a milestone with its collaboration partner, Labège, France-based Antabio, in an antibacterial drug discovery project funded by the Wellcome TrustGoing forward on the Fast Track
GSK’s Discovery Fast Track Challenge begins second year in North America and extends to EuropeClinical Trials
Liver cells combat urea cycle disorders
First data on Cytonet’s liver cell therapy presented at annual meeting of the Society for Inherited Metabolic DisordersLighting up the market with LAIs
Phase 3 data support long-acting injectable aripiprazole lauroxil as a schizophrenia treatmentInsulin issue
Molecular delivery system enhances drug effect in diabetic subjectsTwo is better than one
BioClinica signs $30 million in eClinical contracts with two top-10 pharmasEditor's Focus
Preventing a preventive medicine backlash
There has been a backlash against vaccination in recent years significant enough to let formerly subdued diseases begin to get a foothold again. Is the reason a 'dumbing down' of America or might we need to look at some factors within pharma as well as contributors to this disturbing trend?Commentary
Out of Order: Mutants Among Us
It might be time to start looking at the reasons why some people don't get certain diseases despite so many factors saying they should. Such an approach might help lead us to new ways of preventing or curing what ails us.The future of stem cells faces a Myriad of obstacles
Arguments that stem cells (like genes) are products of nature and unpatentable are wending their way through the federal courts with potentially significant repercussions for the stem cell industryQ&A
Q&A: Hitching a ride to treat acute myeloid leukemia
A discussion with Dr. Kaushik J. Dave and Dr. John Pagel about the potential of a therapeutic platform based on mAbs and alpha particle emittersFeature
